5-140677950-G-A

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_002109.6(HARS1):​c.588C>T​(p.Cys196Cys) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0773 in 1,610,300 control chromosomes in the GnomAD database, including 5,313 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.074 ( 488 hom., cov: 31)
Exomes 𝑓: 0.078 ( 4825 hom. )

Consequence

HARS1
NM_002109.6 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:3

Conservation

PhyloP100: 0.857

Publications

14 publications found
Variant links:
Genes affected
HARS1 (HGNC:4816): (histidyl-tRNA synthetase 1) Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their cognate amino acids. The protein encoded by this gene is a cytoplasmic enzyme which belongs to the class II family of aminoacyl-tRNA synthetases. The enzyme is responsible for the synthesis of histidyl-transfer RNA, which is essential for the incorporation of histidine into proteins. The gene is located in a head-to-head orientation with HARSL on chromosome five, where the homologous genes share a bidirectional promoter. The gene product is a frequent target of autoantibodies in the human autoimmune disease polymyositis/dermatomyositis. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
HARS1 Gene-Disease associations (from GenCC):
  • autosomal dominant Charcot-Marie-Tooth disease type 2W
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae)
  • Usher syndrome type 3B
    Inheritance: AR Classification: STRONG, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), G2P
  • Usher syndrome type 3
    Inheritance: AR Classification: SUPPORTIVE, NO_KNOWN Submitted by: Orphanet, ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.47).
BP6
Variant 5-140677950-G-A is Benign according to our data. Variant chr5-140677950-G-A is described in ClinVar as [Benign]. Clinvar id is 226651.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.857 with no splicing effect.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.0873 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
HARS1NM_002109.6 linkc.588C>T p.Cys196Cys synonymous_variant Exon 6 of 13 ENST00000504156.7 NP_002100.2 P12081-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
HARS1ENST00000504156.7 linkc.588C>T p.Cys196Cys synonymous_variant Exon 6 of 13 1 NM_002109.6 ENSP00000425634.1 P12081-1

Frequencies

GnomAD3 genomes
AF:
0.0744
AC:
11269
AN:
151540
Hom.:
488
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.0646
Gnomad AMI
AF:
0.207
Gnomad AMR
AF:
0.0897
Gnomad ASJ
AF:
0.0367
Gnomad EAS
AF:
0.00270
Gnomad SAS
AF:
0.0946
Gnomad FIN
AF:
0.0791
Gnomad MID
AF:
0.0633
Gnomad NFE
AF:
0.0805
Gnomad OTH
AF:
0.0691
GnomAD2 exomes
AF:
0.0796
AC:
20016
AN:
251300
AF XY:
0.0804
show subpopulations
Gnomad AFR exome
AF:
0.0615
Gnomad AMR exome
AF:
0.129
Gnomad ASJ exome
AF:
0.0328
Gnomad EAS exome
AF:
0.00169
Gnomad FIN exome
AF:
0.0866
Gnomad NFE exome
AF:
0.0760
Gnomad OTH exome
AF:
0.0779
GnomAD4 exome
AF:
0.0776
AC:
113172
AN:
1458642
Hom.:
4825
Cov.:
29
AF XY:
0.0781
AC XY:
56681
AN XY:
725828
show subpopulations
African (AFR)
AF:
0.0590
AC:
1973
AN:
33414
American (AMR)
AF:
0.123
AC:
5499
AN:
44718
Ashkenazi Jewish (ASJ)
AF:
0.0316
AC:
826
AN:
26122
East Asian (EAS)
AF:
0.000806
AC:
32
AN:
39686
South Asian (SAS)
AF:
0.106
AC:
9119
AN:
86170
European-Finnish (FIN)
AF:
0.0868
AC:
4638
AN:
53416
Middle Eastern (MID)
AF:
0.0543
AC:
313
AN:
5760
European-Non Finnish (NFE)
AF:
0.0781
AC:
86617
AN:
1109064
Other (OTH)
AF:
0.0689
AC:
4155
AN:
60292
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.460
Heterozygous variant carriers
0
4877
9754
14631
19508
24385
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
3168
6336
9504
12672
15840
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0743
AC:
11264
AN:
151658
Hom.:
488
Cov.:
31
AF XY:
0.0760
AC XY:
5625
AN XY:
74058
show subpopulations
African (AFR)
AF:
0.0644
AC:
2661
AN:
41294
American (AMR)
AF:
0.0896
AC:
1361
AN:
15198
Ashkenazi Jewish (ASJ)
AF:
0.0367
AC:
127
AN:
3462
East Asian (EAS)
AF:
0.00271
AC:
14
AN:
5168
South Asian (SAS)
AF:
0.0945
AC:
452
AN:
4784
European-Finnish (FIN)
AF:
0.0791
AC:
832
AN:
10520
Middle Eastern (MID)
AF:
0.0578
AC:
17
AN:
294
European-Non Finnish (NFE)
AF:
0.0805
AC:
5468
AN:
67924
Other (OTH)
AF:
0.0684
AC:
144
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
482
965
1447
1930
2412
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
130
260
390
520
650
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0743
Hom.:
461
Bravo
AF:
0.0733
Asia WGS
AF:
0.0340
AC:
117
AN:
3478
EpiCase
AF:
0.0725
EpiControl
AF:
0.0710

ClinVar

Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:2
Feb 04, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

p.Cys196Cys in exon 6 of HARS: This variant is not expected to have clinical sig nificance because it does not alter an amino acid residue and is not located wit hin the splice consensus sequence. It has been identified in 8% (9547/121084) of pan ethnic chromosomes including over 400 homozygous individuals by the Exome A ggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs2230361). -

May 09, 2017
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Usher syndrome type 3B Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.47
CADD
Benign
11
DANN
Benign
0.80
PhyloP100
0.86
Mutation Taster
=96/4
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.020
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2230361; hg19: chr5-140057535; COSMIC: COSV56910222; COSMIC: COSV56910222; API